Trial Profile

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cedazuridine/decitabine (Primary) ; Iadademstat
Indications Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
Focus Therapeutic Use

04 Nov 2025 According to an Oryzon media release, this study is sponsored and conducted by the NCI, and recently started to enroll patients.
04 Nov 2025 According to an Oryzon media release, trial design of this study will be presented as a Trial in progress Poster by Dr. Anand Patel, at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2025, in Orlando, Florida (USA).
21 May 2025 Planned number of patients changed from 56 to 62.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com